This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Click here for VELSIPITY▼ (etrasimod) Prescribing Information. Adverse event reporting can be found at the bottom of the page.
Menu
Close
VELSIPITY is indicated for the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.1
Deliver on your patients' preference for oral treatment
The treatment landscape for UC in the UK is changing:
Multiple oral advanced treatments* in UC have been approved since 20181–23
The NHS has committed through its Long-Term Plan to administering appropriate therapy 'closer to home' to provide treatment options for patient which may reduce the operational and financial burden on hospitals and healthcare providers24
*Advanced treatments in UC are defined as biologics, S1P receptor modulators and JAK inhibitors.25
Discover the possibilites on the route where clinicial goals and patient preferences can converge
It is believed that therapy options should be as convenient as possible for patients with UC, as this is a disease with a high symptom burden, which impacts patients' freedom and independence26–34
The availability of multiple oral advanced therapies* provides physicians with the treatment options to meet their patients' preferences.4–24,26–28
*Advanced treatments in UC are defined as biologics, S1P receptor modulators and JAK inhibitors.25
Second Accordion Content
First Accordion Content
Second Accordion Content
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2025 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024